First-generation vaccines against human papillomavirus

Area of Science:

• Vaccinology
• Virology
• Public Health

Background:

• Significant advancements in human papillomavirus (HPV) vaccine development have occurred over the last decade.
• The discovery of HPV virus-like particles has been pivotal in creating effective vaccine candidates.
• A licensed HPV vaccine would be the first for a prevalent sexually transmitted infection.

Purpose of the Study:

• To review the progress in prophylactic human papillomavirus vaccine development.
• To highlight the promising results from recent clinical trials of HPV vaccine candidates.
• To assess the safety and efficacy of emerging HPV vaccines.

Main Methods:

• Review of preclinical studies on HPV vaccine candidates.
• Analysis of recent clinical trial data for HPV vaccines.
• Evaluation of vaccine tolerability, antibody induction, and prevention of infection/disease.

Main Results:

• Attractive vaccine candidates have emerged from preclinical research.
• Recent clinical trials demonstrate highly promising outcomes.
• Candidate vaccines are well-tolerated, induce high antibody titers, and effectively prevent HPV infection and early disease.

Conclusions:

• Licensure of an HPV vaccine is anticipated in the near future.
• The development represents a significant milestone in preventing sexually transmitted infections.
• Current HPV vaccine candidates show strong potential for preventing infection and associated clinical conditions.